Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 18/20 | 0.63 |
| ▸ | ADAMTS5 | Q9UNA0 | 10/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22063176 | 0.86 | ADAM17 (0.60) | ADAM17ADAMTS5 | |
| SCHEMBL22063185 | 0.86 | ADAM17 (0.63) | ADAM17ADAMTS5 | |
| SCHEMBL22062952 | 0.85 | ADAM17 (0.55) | ADAM17ADAMTS5 | |
| SCHEMBL19701926 | 0.84 | ADAM17 (0.86) | ADAM17ADAMTS5 | |
| SCHEMBL19703097 | 0.84 | ADAM17 (0.86) | ADAM17ADAMTS5 | |
| SCHEMBL22063177 | 0.81 | ADAM17 (0.73) | ADAM17ADAMTS5 | |
| SCHEMBL19692241 | 0.80 | ADAMTS5 (0.69) | ADAM17ADAMTS5 | |
| SCHEMBL21403951 | 0.80 | ADAMTS5 (0.69) | ADAM17ADAMTS5 | |
| SCHEMBL19692407 | 0.79 | ADAM17 (0.56) | ADAM17ADAMTS5 | |
| SCHEMBL19703167 | 0.78 | ADAMTS5 (0.60) | ADAM17ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3468961-B1 | 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2020-06-10 | — | — | EP | disclosed |
| WO-2017211667-A1 | 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2017-12-14 | — | — | WO | disclosed |